** Shares of cancer diagnostics firm Personalis PSNL.O fall 5.9% to $14.49 premarket

** Tempus AI TEM.O is acquiring Personalis in a deal valued at $1.5 billion

** Personalis shareholders will receive $16.25/share, a 5.6% premium to the last closing price of $15.39

** Tempus will gain access to Personalis' NeXT Personal cancer test, which helps detect tiny amounts of tumor DNA to monitor treatment response and identify cancer recurrence early

** The deal expected to close in late 2026 or early 2027

** Tempus AI shares down 4.4% at $50.18 before the bell

** As of last close, PSNL up 93.3%, TEM down 11% YTD